The single domain antibody (sdAb) platforms market is rapidly expanding, driven by the increasing use of these powerful tools in therapeutic development, diagnostics, and research. Also known as nanobodies, single domain antibodies stand out due to their small size, high stability, and ability to bind with high affinity to epitopes that are typically inaccessible to traditional antibodies. This unique characteristic makes them particularly valuable for addressing unmet needs in oncology, immunology, infectious diseases, and neurology.

The market growth is further propelled by the rising demand for biologics, advancements in antibody engineering, and the growing integration of single domain antibodies in next-generation treatments such as bispecific antibodies and antibody-drug conjugates. According to Persistence Market Research, the global market for single domain antibody platforms is expected to reach US$ 32.7 million by 2024 and continue expanding at a robust CAGR of 9.5%, reaching US$ 62.3 million by 2031.

The oncology sector currently leads the market, fueled by intensive research and development of targeted therapies. North America holds the largest market share, supported by a well-established biopharmaceutical infrastructure, substantial R&D investments, and strong regulatory frameworks. Meanwhile, Europe and Asia-Pacific are emerging as significant contributors, with Europe leveraging its thriving biotech ecosystem, and Asia-Pacific benefiting from growing investments in life sciences and drug discovery.

Source: OpenPR